PeopleBeatingCancer supports an evidence-based integrative approach to cancer care. For most newly diagnosed patients, FDA-approved therapies form the foundation of treatment, while evidence-based complementary therapies may help reduce side effects and improve survivorship.
Click the orange button to the right to learn more.
Chemotherapy-Induced Nephrotoxicity: Protecting Your Kidneys During Cancer Treatment. Chemotherapy saves lives. Unfortunately, some of the most effective cancer drugs can also damage the kidneys.
Kidney injury (nephrotoxicity) is one of the most important dose-limiting side effects of chemotherapy. While some patients experience only temporary changes in kidney function, others may develop chronic kidney disease (CKD) that affects long-term health.
The good news is that many cases of chemotherapy-induced nephrotoxicity can be prevented or minimized through careful monitoring, hydration, medication adjustments, and healthy lifestyle choices.
I am a long-term survivor of an incurable blood cancer called multiple myeloma.
I was floored when I discovered how often cancer patients developed chemotherapy-induced nephrotoxicity either from their cancer or from one of the therapies they received.
My advice is to undergo regular blood work, especially eGFR, creatinine, and BUN testing in order to keep an eye on your kidney health.
My research and experience with evidence-based non-conventional therapies are the reasons why I have lived in complete remission from my incurable blood cancer since achieving complete remission in early 1999. I have learned that the best way to manage aggressive cancers is to combine the best of conventional and evidence-based non-conventional therapies.
I have come to believe that therapy-induced side effects can be life-threatening while ruining quality of life. Consider therapies shown to reduce possible side effects.
Scroll down the page and post a question or a comment if there’s anything you’d like to know about chemotherapy-induced nephrotoxicity.
Good luck,
Nephrotoxicity refers to damage to the kidneys caused by medications.
Because the kidneys filter nearly 180 liters of blood every day, they are exposed to high concentrations of chemotherapy drugs and their breakdown products.
Kidney injury may occur:
Damage may involve:
Recent reviews emphasize that kidney complications include acute kidney injury, electrolyte disturbances, chronic kidney function loss, thrombotic microangiopathy, and glomerular injury depending on the chemotherapy agent used.
Several commonly used chemotherapy drugs are associated with nephrotoxicity.
Among these, cisplatin remains the best-known cause of chemotherapy-related kidney injury, largely because it accumulates in kidney tubule cells and causes oxidative stress, inflammation, and cell death.
Early kidney injury often causes no symptoms at all.
Later symptoms may include:
Because symptoms often appear late, routine blood work is essential.
Some patients are much more vulnerable than others.
Risk factors include:
Cancer itself may also impair kidney function through dehydration, infection, light-chain disease (multiple myeloma), urinary obstruction, or tumor lysis syndrome.
Different drugs injure different parts of the kidney.
Causes:
May result in:
High-dose methotrexate may:
Adequate hydration and urine alkalinization substantially reduce this risk.
May damage the proximal tubules.
Possible complications include:
Rarely causes:
Patients receiving nephrotoxic chemotherapy usually undergo regular laboratory monitoring.
Typical tests include:
Monitoring before each chemotherapy cycle allows clinicians to detect problems early and adjust treatment when necessary.
Hydration is the single most effective preventive strategy.
Many chemotherapy protocols include:
Hydration reduces the concentration of chemotherapy drugs in the kidneys and helps flush them from the body.
Cisplatin commonly causes magnesium depletion.
Several studies suggest magnesium supplementation may reduce kidney injury in patients receiving cisplatin, although supplementation should always be guided by the oncology team.
Patients should avoid unnecessary exposure to:
Always review over-the-counter medications and supplements with your oncologist.
For high-dose methotrexate:
These measures reduce crystal formation inside the kidneys.
Oncologists frequently reduce chemotherapy doses based on:
Individualized dosing can preserve kidney function while maintaining cancer treatment effectiveness.
While lifestyle measures cannot eliminate chemotherapy toxicity, they may help support overall kidney health.
Focus on:
High blood pressure accelerates kidney damage.
Poor diabetes control greatly increases kidney injury risk.
Regular moderate exercise:
Smoking accelerates kidney disease progression.
Researchers continue investigating therapies that may protect the kidneys during chemotherapy.
Potential candidates include:
None should be started without discussing them with your oncology team because some supplements may interfere with chemotherapy or may not be appropriate for your specific cancer or treatment plan.
Chemotherapy-induced nephrotoxicity is common but often preventable. The highest-risk drugs—including cisplatin, ifosfamide, and high-dose methotrexate—require careful monitoring and proactive prevention.
Simple interventions such as adequate hydration, avoiding additional kidney toxins, monitoring kidney function, correcting electrolyte abnormalities, and promptly reporting symptoms can substantially reduce the risk of long-term kidney damage while allowing patients to continue life-saving cancer treatment.
| Therapy | Evidence | My Rating |
|---|---|---|
| IV hydration | Multiple clinical studies; standard of care | ⭐⭐⭐⭐⭐ Strong evidence |
| Chemotherapy dose adjustment by kidney function | Standard oncology practice | ⭐⭐⭐⭐⭐ Strong evidence |
| Magnesium replacement (cisplatin) | Good clinical evidence | ⭐⭐⭐⭐☆ Moderate-Strong |
| Urine alkalinization for high-dose methotrexate | Standard of care | ⭐⭐⭐⭐⭐ Strong evidence |
| Avoid NSAIDs and other nephrotoxins | Strong observational and clinical evidence | ⭐⭐⭐⭐⭐ Strong evidence |
| Sodium thiosulfate (selected cisplatin settings) | Good evidence in specific populations | ⭐⭐⭐⭐☆ Moderate-Strong |
| Curcumin | Primarily laboratory and animal studies | ⭐⭐☆☆☆ Preliminary |
| Melatonin | Early clinical/preclinical evidence | ⭐⭐☆☆☆ Preliminary |
| N-acetylcysteine | Mixed clinical evidence | ⭐⭐☆☆☆ Mixed |
Interpretation: Five stars indicate strong human clinical evidence or established standard-of-care recommendations. Lower ratings reflect promising but limited human evidence and should not be interpreted as proof of benefit.
Given your existing content, I would link this article to: